Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
• By PharmAsia News
SEOUL - South Korean biotech Celltrion plans on speeding up development of its biosimilars by selling a 10 percent stake in the company to Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.
CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.
Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.